BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

Tech entrepreneur and Tesla (TSLA, Financials) CEO Elon Musk's disclosure of using weight-loss pharmaceuticalsincluding Eli Lilly's (LLY, Financials) Mounjaro and Novo Nordisk's Ozempichas drawn ...